Skip to content
★ Sign in to follow
코오

코오롱생명과학 Stock: price and insider trades · South Korea

KR·Mcap ₩169.9BHealth Care

No insider purchase over the last 90 days. The latest, by 그린이에스지성장제1호사모투자, was filed 02 Dec 2025.

코오롱생명과학: what insiders have been doing

Every trade that managers of 코오롱생명과학 disclose to DART (FSS) is tracked on this page. The company sits in the Health Care sector. Between 9 November 2025 and 9 November 2026, 1 insider published 1 filing.

Every open-market trade in the period is a purchase: 1 purchase, from 1 insider, and not a single sale. The amount is not disclosed for 1 filing. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. The buyers include 1 major shareholder.

With 1 filing in twelve months, the company is quieter than the median of 7 filings across the 2,648 companies we follow on the same exchange. The full history, which starts in 2021, counts 10 purchases against 2 sales.

The clock since the last published purchase (2 December 2025) now reads 342 days.

Elsewhere in the same sector, our signals recently picked up insider purchases at Cooper Companies, Inc. and Cytosorbents Corp. Source: insider filings from DART (FSS). Past trades are no guide to future returns.

Insider Decl.
14
Thresholds
n/a
Buy Volume
n/a
10 ops. · all time
Sell Volume
n/a
2 ops. · all time

Who traded when

BuySale
그린이에스지성장제1호사모투자1 buy
Fundamental score
Ranked 10,286 of 26,913 companies
57.4
score / 100
Value
62
Quality
53
FCF yld-17%
Earn yld15%
EV/EBITDA6.3x
ROE·
Gross mgn27%
Net mgn12%
Debt/EBITDA2.4x
Pillars2/3

Transparent value + quality ranking, distinct from the insider signal.

Financial data

as of FY 2025

FY ended December 2025 · cache

₩12,980
Analyst consensus
·
Income statement
Revenue₩209B
Gross profit₩55.9B27% margin
EBITDA₩43.3B21% margin
Net income₩25B11.9% margin
Balance sheet & cash
Market cap₩169.9B
Total debt₩103.7B
Free Cash Flow-₩28.2B
Last declaration on 2 December 2025
Declarations14 total
  • ▲
    대량보유자Executives
    0DART
    914,076 sharesKRXDART:20251202000195
    Canonical exit: 24 Feb 2026 (T+90)
  • ▼
    Executives
    0DART
    298,713 sharesKRXDART:20241108000533
  • ▲
    -Executives
    0DART
    ShareKRXDART:20240625000309
    Canonical exit: 19 Sept 2024 (T+90)
  • ▲
    Executives
    0DART
    919,120 sharesKRXDART:20240625000305
    Canonical exit: 19 Sept 2024 (T+90)
  • ▲
    Executives
    0DART
    689,338 sharesKRXDART:20240625000425
    Canonical exit: 18 Sept 2024 (T+90)
  • ●
    Executives
    Executives(filed)
    0DART
  • ▲
    Executives(filed)
    0DART
    919,120 sharesKRXDART:20230331003653
    Canonical exit: 29 Jun 2023 (T+90)
  • ▲
    Executives(filed)
    0DART
    919,120 sharesKRXDART:20230222002768
    Canonical exit: 23 May 2023 (T+90)
  • ▲
    Executives
    0DART
    510,066 sharesShareKRXDART:20230222002797
    Canonical exit: 23 May 2023 (T+90)
  • ▼
    대량보유자Executives(filed)
    0DART
    3,517 sharesKRXDART:20230106000472
  • ▲
    Executives
    0DART
    525 sharesShareKRXDART:20230106000461
    Canonical exit: 1 Apr 2023 (T+90)
  • ▲
    Executives(filed)
    0DART
    919,120 sharesKRXDART:20211216000105
    Canonical exit: 16 Mar 2022 (T+90)
  • ▲
    Executives(filed)
    0DART
    919,120 sharesKRXDART:20210728000337
    Canonical exit: 26 Oct 2021 (T+90)
  • ●
    Executives
    Executives(filed)
    0DART

14 of 14 declarations

About 코오롱생명과학

Kolon Life Science is a company specializing in the health and pharmaceutical sector, listed on the XKRX market. It focuses on the development of biopharmaceutical products and innovative therapies.